首次在人类,多中心,开放标签,ATOR-1017 (evunzekibart) 的第一阶段研究,4-1BB抗体,在患有晚期固体恶性瘤的患者中进行
Ana Carneiro1, Amanda Hahn2,3, Peter Ellmark4,5
1Skåne University Hospital and Lund University, Lund, Sweden.
Journal for immunotherapy of cancer
|January 23, 2025
概括
针对4-1BB的新型抗体ATOR-1017在患有晚期固体瘤的患者中表现出良好的安全性. 治疗显示出生物活性,并导致近三分之一的参与者长期稳定疾病.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- ATOR-1017 (evunzekibart) 是一种人类IgG4抗体,其向4-1BB共刺激受体.
- 它激活T细胞和自然杀手细胞,促进免疫介导的瘤细胞死亡.
研究的目的:
- 为了评估ATOR-1017的安全性和耐受性,在第一次在人体上进行I期研究.
- 为了确定ATOR-1017的最大耐受剂量 (MTD),药理动力学,免疫性和初步疗效.
主要方法:
- 一个多中心的I期研究,涉及每21天内静脉注射ATOR-1017,用于晚期固体瘤患者.
- 剂量升级使用单个患者队列和修改后的3+3设计.
- 使用RECIST标准评估不良事件,剂量限制性毒性,药理动力学,免疫性和临床反应.
主要成果:
- 没有达到ATOR-1017的MTD. 52%的患者经历了与治疗相关的不良事件 (TRAEs),最常见的是疲劳和中性质减退.
- 没有患者因TRAE而停止治疗,也没有观察到剂量限制性毒性.
- 52%的患者实现了稳定的疾病,24%的患者维持了超过6个月. 剂量依赖的PD生物标志物的增加表明了目标参与.
结论:
- 发现ATOR-1017是安全的,在所有剂量水平上都能耐受,并表现出生物活性.
- 初步的疗效数据,包括大量重度预治疗患者的长期稳定疾病,支持进一步的临床开发.
- 需要对ATOR-1017进行进一步的研究,可能用于组合疗法.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.


